Читать книгу Current Concepts in Movement Disorder Management - Группа авторов - Страница 61

As the impact of MAO-B inhibitors (either selegiline or rasagiline) on motor symptoms is less significant when compared to both DAs and levodopa, they are used as a first-line treatment when symptoms are mild. A potential disease-modifying effect of rasagiline 1 mg has been reported by the ADAGIO study but not confirmed by additional clinical trial evidence [10].